Adverum Biotechnologies (ADVM) Misses Q1 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Adverum Biotechnologies Announces New INFINITY Phase 2 Trial for ADVM-022 in Diabetic Macular Edema, Reports Recent Business Progress and First Quarter 2020 Financial Results
May 28, 2020 4:01 PM EDT-- INFINITY is a randomized, active comparator-controlled trial --
-- INFINITY trial initiated for patients with diabetic macular edema, the most common cause of vision loss in people with diabetic retinopathy --
-- Positive interim clinical data recently presented for ADVM-022 in OPTIC Phase 1 trial for wet AMD; data from all four cohorts expected to be presented by year-end --
-- Company to host conference call today at 1:30 pm PDT / 4:30 pm EDT --
REDWOOD CITY, Calif., May 28, 2020 (GLOBE NEWSWIRE) --... More
